Portal de Periódicos da CAPES

Understanding EMPA-REG OUTCOME

2015; Elsevier BV; Volume: 3; Issue: 12 Linguagem: Inglês

10.1016/s2213-8587(15)00424-6

2213-8595

Marcel H.A. Muskiet, Daniël H. van Raalte, Erik J.M. van Bommel, Mark M. Smits, Lennart Tonneijck,

Pancreatic function and diabetes

The EMPA-REG OUTCOME study,1 in which the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin showed impressive benefits on cardiovascular mortality, all-cause mortality, and hospital admission for heart failure, could change type 2 diabetes management in years to come.2 The remarkable effect size and rapid onset (<3 months) were unexpected, which suggests a need for an improved understanding of the mechanisms involved to fully exploit the clinical benefits of this antihyperglycaemic drug.